LTGO · Latigo Biotherapeutics, Inc. · Debt
$15.26
+0.24 (+1.60%)
At close · Oct 26
Return incl. dividend (before tax)
Going-concern doubt
— cleared Sep 3, 2026
The latest filing states the doubt was alleviated.
“Accordingly, the prior substantial doubt about the Company's ability to continue as a going concern has been alleviated.”View the 10-Q filed Sep 3, 2026
Market Cap
$954.38M
Shares
66.30M
Volume · Oct 26
165.33K
Avg daily vol (56 sessions)
349.92K
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Convertible notes payable, including current maturities | 2026-06-30 | USD 35,000,000 | 10-Q filed 2026-09-03 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Current operating lease liabilities | 2026-06-30 | USD 705,000 | 10-Q filed 2026-09-03 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 648,000 | 10-Q filed 2026-09-03 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.